Budd-Chiari Syndrome: Long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt

<p>Abstract</p> <p>Background</p> <p>Budd-Chiari syndrome (BCS) generally implies thrombosis of the hepatic veins and/or the intrahepatic or suprahepatic inferior vena cava. Treatment depends on the underlying cause, the anatomic location, the extent of the thrombotic process and the functional capacity of the liver. It can be divided into medical treatment including anticoagulation and thrombolysis, radiological procedures such as angioplasty and transjugular intrahepatic porto-systemic shunt (TIPS) and surgical interventions including orthotopic liver transplantation (OLT). Controlled trials or reports on larger cohorts are limited due to rare disease frequency. The aim of this study was to report our single centre long term results of patients with BCS receiving one of three treatment options i.e. medication only, TIPS or OLT on an individually based decision of our local expert group.</p> <p>Methods</p> <p>20 patients with acute, subacute or chronic BCS were treated between 1988 and 2008. Clinical records were analysed with respect to underlying disease, therapeutic interventions, complications and overall outcome.</p> <p>Results</p> <p>16 women and 4 men with a mean age of 34 ± 12 years (range: 14-60 years) at time of diagnosis were included. Myeloproliferative disorders or a plasmatic coagulopathy were identified as underlying disease in 13 patients, in the other patients the cause of BCS remained unclear. 12 patients presented with an acute BCS, 8 with a subacute or chronic disease. 13 patients underwent TIPS, 4 patients OLT as initial therapy, 2 patients required only symptomatic therapy, and one patient died from liver failure before any specific treatment could be initiated. Eleven of 13 TIPS patients required 2.5 ± 2.4 revisions (range: 0-8). One patient died from his underlying hematologic disease. The residual 12 patients still have stable liver function not requiring OLT. All 4 patients who underwent OLT as initial treatment, required re-OLT due to thrombembolic complications of the graft. Survival in the TIPS group was 92.3% and in the OLT group 75% during a median follow-up of 4 and 11.5 years, respectively.</p> <p>Conclusion</p> <p>Our results confirm the role of TIPS in the management of patients with acute, subacute and chronic BCS. The limited number of patients with OLT does not allow to draw a meaningful conclusion. However, the underlying disease may generate major complications, a reason why OLT should be limited to patients who cannot be managed by TIPS.</p

A new optional vena cava filter: Retrieval at 12 weeks in an animal model

PURPOSE: To test the feasibility and safety of percutaneous retrieval of a new inferior vena cava (IVC) filter, the Recovery Filter (RF), acutely and after 12-week implantation in sheep. MATERIALS AND METHODS: The RF is a bilevel filter with stabilizing arms and elastic hooks that allow retrieval with a unique retrieval cone after incorporation into the wall of the IVC. Twenty-four filters were placed in the infrarenal IVCs of 18 sheep. In six sheep, two filters were placed and then removed immediately; three sheep were killed acutely and three were killed after a healing period of 3 weeks. In 12 sheep, a single filter was placed and then removed 12 weeks later; six were killed after retrieval and six were killed after an 8-week healing period. RESULTS: The mean (+/-SD) transverse vena caval diameter was 15.3 mm +/- 2. All filters were deployed as intended and retrieved without difficulty. At sacrifice, there was no evidence of IVC perforation or retroperitoneal abnormality. The IVCs of the animals in the acute retrieval group showed minimal acute superficial injury that was largely reversed at 3 weeks. At 12 weeks, there was evidence of transmural incorporation of filter elements with narrowing of the IVCs. Solitary fibrotic abnormalities were present in the aorta adjacent to IVC lesions in nine of the 12 animals in the 12-week group. The IVC and aortic abnormalities were largely healed, with reversal of IVC narrowing after 8 weeks. CONCLUSION: The recovery filter can be reliably and safely retrieved acutely and 12 weeks after implantation in sheep

A New Occlusion Device: Application of the ArtVentive Endoluminal Occlusion System (EOS)- First in Human Clinical Trial

PURPOSE: The purpose of this study was to determine the safety and efficacy of a new endoluminal occlusion device, ArtVentive endoluminal occlusion system (EOS), to occlude the spermatic vein in symptomatic males with varicoceles. METHODS: The ArtVentive EOS device has been developed for percutaneous, peripheral occlusion of the peripheral arterial and venous vasculature. The system is comprised of an implantable occlusion device and a delivery catheter. At present, there are two device sizes: (a) size 1 for target vessels ranging between 3.5 and 5.5 mm in diameter, and (b) size 2 for target vessels 5.5-8.5 mm in diameter. The treatment group included six adult males, ages 22-34 years. Nine target vessels were occluded. A total of 20 devices were implanted in six subjects. RESULTS: The acute occlusion rate at the end of the procedure was 100 % occurring in nine of nine vessels. The spermatic veins of all patients remained occluded on venography at 30 days follow-up. Pain scores related to varicoceles decreased in five of six patients. CONCLUSIONS: Although we recognize this study is limited, initial experience indicates that the ArtVentive EOS is a safe and effective new device for occlusion of vessels (varicoceles). The device has potential applications in other clinical conditions requiring occlusion of veins or arteries